

REMARKS/ARGUMENTS

Claims 1, 9-12 and 27-31 are pending. Claims 1, 9, 12 have been amended to add “the complement of” and claim 31 has been amended to add “the complementary sequence of,” as the nucleic acids disclosed therein are to be contacted with a cellular sample in order to hybridize to mRNA in the sample. Thus, these nucleic acids should be the complementary sequence to SEQ ID NO: 13, 15 or 17. Further, the claim amendments listed herein are identical to the Examiner’s proposed amendments dated September 20, 2010. No new matter is added.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is respectfully requested. If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:ack
63007176 v1